Literature DB >> 22925115

Fibrinolytic activity in cerebrospinal fluid of dogs with different neurological disorders.

C de la Fuente1, L Monreal, J Cerón, J Pastor, J Viu, S Añor.   

Abstract

BACKGROUND: Fibrinolytic activity in cerebrospinal fluid (CSF) is activated in humans by different pathologic processes.
OBJECTIVES: To investigate fibrinolytic activity in the CSF of dogs with neurological disorders by measuring CSF D-dimer concentrations. ANIMALS: One hundred and sixty-nine dogs with neurological disorders, 7 dogs with systemic inflammatory diseases without central nervous system involvement (SID), and 7 healthy Beagles were included in the study. Dogs with neurological disorders included 11 with steroid-responsive meningitis-arteritis (SRMA), 37 with other inflammatory neurological diseases (INF), 38 with neoplasia affecting the central nervous system (NEO), 28 with spinal compressive disorders (SCC), 15 with idiopathic epilepsy (IE), and 40 with noninflammatory neurological disorders (NON-INF).
METHODS: Prospective observational study. D-dimers and C-reactive protein (CRP) were simultaneously measured in paired CSF and blood samples.
RESULTS: D-dimers and CRP were detected in 79/183 (43%) and in 182/183 (99.5%) CSF samples, respectively. All dogs with IE, SID, and controls had undetectable concentrations of D-dimers in the CSF. CSF D-dimer concentrations were significantly (P < .001) higher in dogs with SRMA than in dogs with other diseases and controls. CSF CRP concentration in dogs with SRMA was significantly (P < .001) higher than in dogs of other groups and controls, except for the SID group. No correlation was found between blood and CSF D-dimer concentrations. CONCLUSIONS AND CLINICAL IMPORTANCE: Intrathecal fibrinolytic activity seems to be activated in some canine neurological disorders, and it is high in severe meningeal inflammatory diseases. CSF D-dimer concentrations may be considered a diagnostic marker for SRMA.
Copyright © 2012 by the American College of Veterinary Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22925115     DOI: 10.1111/j.1939-1676.2012.00991.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  6 in total

1.  Acute Phase Proteins in Cerebrospinal Fluid from Dogs with Naturally-Occurring Spinal Cord Injury.

Authors:  Kimberly M Anderson; C Jane Welsh; Colin Young; Gwendolyn J Levine; Sharon C Kerwin; C Elizabeth Boudreau; Ismael Reyes; Armando Mondragon; John F Griffin; Noah D Cohen; Jonathan M Levine
Journal:  J Neurotrauma       Date:  2015-07-17       Impact factor: 5.269

2.  Isobaric Labeling Strategy Utilizing 4-Plex N,N-Dimethyl Leucine (DiLeu) Tags Reveals Proteomic Changes Induced by Chemotherapy in Cerebrospinal Fluid of Children with B-Cell Acute Lymphoblastic Leukemia.

Authors:  Qinying Yu; Xiaofang Zhong; Bingming Chen; Yu Feng; Min Ma; Carol A Diamond; Julie S Voeller; Miriam Kim; Kenneth B DeSantes; Christian M Capitini; Neha J Patel; Margo L Hoover-Regan; Michael J Burke; Kimberly Janko; Diane M Puccetti; Chrysanthy Ikonomidou; Lingjun Li
Journal:  J Proteome Res       Date:  2020-05-27       Impact factor: 4.466

Review 3.  Immune-Mediated Central Nervous System Disease-Current Knowledge and Recommendations.

Authors:  Samantha Vitale; Kari Foss
Journal:  Top Companion Anim Med       Date:  2018-12-04

4.  Successful surgical and medical treatment of a severe, acute epidural bleed in a young dog due to steroid responsive meningitis-arteritis.

Authors:  Jessica Zilli; Agnieszka Olszewska; Daniela Farke; Martin Jürgen Schmidt
Journal:  Acta Vet Scand       Date:  2021-07-10       Impact factor: 1.695

Review 5.  Advances in diagnostic and treatment modalities for intracranial tumors.

Authors:  P J Dickinson
Journal:  J Vet Intern Med       Date:  2014-05-09       Impact factor: 3.333

Review 6.  Canine Primary Intracranial Cancer: A Clinicopathologic and Comparative Review of Glioma, Meningioma, and Choroid Plexus Tumors.

Authors:  Andrew D Miller; C Ryan Miller; John H Rossmeisl
Journal:  Front Oncol       Date:  2019-11-08       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.